These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10429238)

  • 21. From laboratory to Phase I/II cancer trials with recombinant biotherapeutics.
    Tolner B; Smith L; Hillyer T; Bhatia J; Beckett P; Robson L; Sharma SK; Griffin N; Vervecken W; Contreras R; Pedley RB; Begent RH; Chester KA
    Eur J Cancer; 2007 Nov; 43(17):2515-22. PubMed ID: 17933516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commercial challenges of protein drug delivery.
    Brown LR
    Expert Opin Drug Deliv; 2005 Jan; 2(1):29-42. PubMed ID: 16296733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recombinant immunotoxin for cancer therapy: current status and prospective].
    Nagata S
    Tanpakushitsu Kakusan Koso; 2001 Mar; 46(4 Suppl):540-6. PubMed ID: 11268658
    [No Abstract]   [Full Text] [Related]  

  • 25. [General principles and first clinical trials of therapeutic vaccines against cancer].
    Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
    Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovering and improving novel peptide therapeutics.
    McGregor DP
    Curr Opin Pharmacol; 2008 Oct; 8(5):616-9. PubMed ID: 18602024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergies of microtissue design, viral transduction and adjustable transgene expression for regenerative medicine.
    Kelm JM; Kramer BP; Gonzalez-Nicolini V; Ley B; Fussenegger M
    Biotechnol Appl Biochem; 2004 Feb; 39(Pt 1):3-16. PubMed ID: 12968952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translating new insights into treatment optimisation in multiple sclerosis.
    Fazekas F; Kieseier BC
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857
    [No Abstract]   [Full Text] [Related]  

  • 29. Peptides as tools and drugs for immunotherapies.
    Beck A; Klinguer-Hamour C; Bussat MC; Champion T; Haeuw JF; Goetsch L; Wurch T; Sugawara M; Milon A; Van Dorsselaer A; Nguyen T; Corvaïa N
    J Pept Sci; 2007 Sep; 13(9):588-602. PubMed ID: 17602441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdominant genetics, peptide inhibitors and drug targets.
    Kamb A; Teng DH
    Curr Opin Mol Ther; 2000 Dec; 2(6):662-9. PubMed ID: 11249744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delivery of peptides to the brain: emphasis on therapeutic development.
    Banks WA
    Biopolymers; 2008; 90(5):589-94. PubMed ID: 18335425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Peptides used in lowering the level of LDL in plasma when treating familial hypercholesterolemia].
    Sun L; Yue Y; Yu X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Jun; 20(2):336-9. PubMed ID: 12856614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advancing TB vaccines to Phase I clinical trials in the US: regulatory/manufacturing/licensing issues.
    Rowland SS; Mayner RL; Barker L
    Tuberculosis (Edinb); 2005; 85(1-2):39-46. PubMed ID: 15687026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptides as drugs: is there a market?
    Loffet A
    J Pept Sci; 2002 Jan; 8(1):1-7. PubMed ID: 11831558
    [No Abstract]   [Full Text] [Related]  

  • 36. Consideration of the proteins and peptides produced by new technology for use as therapeutics.
    Liu DT; Goldman N; Gates F
    Lymphokine Res; 1986; 5 Suppl 1():S189-92. PubMed ID: 3537548
    [No Abstract]   [Full Text] [Related]  

  • 37. Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools.
    Heymann D; Fortun Y; Rédini F; Padrines M
    Drug Discov Today; 2005 Feb; 10(4):242-7. PubMed ID: 15708742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide Developability at the Discovery-to-Development Interface--Current State and Future Opportunities.
    Bak A; Dai W
    AAPS J; 2015 Jul; 17(4):777-9. PubMed ID: 25823670
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiovascular Response to a Modern Roller Coaster RideCardiovascular Response to a Modern Roller Coaster Ride.
    JAMA; 2007 Aug; 298(7):739-741. PubMed ID: 22600378
    [No Abstract]   [Full Text] [Related]  

  • 40. Peptides 2020: A Clear Therapeutic Vision.
    Angell Y; Holford M; Moos WH
    Protein Pept Lett; 2018; 25(12):1042-1043. PubMed ID: 30706773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.